Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19035896 | 0.86 | MMP2 (0.37) | LMNAPKMKDM4ENPC1CYP3A4 | |
| SCHEMBL17486690 | 0.84 | MMP2 (0.39) | LMNAPKMKDM4ENPC1CYP3A4 | |
| SCHEMBL17476471 | 0.84 | KDM4E (0.39) | LMNAKDM4EMEN1KMT2AHPGD | |
| SCHEMBL17476470 | 0.84 | KDM4E (0.39) | LMNAKDM4EMEN1KMT2AHPGD | |
| SCHEMBL12347419 | 0.82 | MMP2 (0.40) | LMNAPKMKDM4ENPC1CYP3A4 | |
| SCHEMBL17231208 | 0.80 | MMP2 (0.34) | — | |
| SCHEMBL14682659 | 0.80 | MMP2 (0.39) | LMNAPKMKDM4ENPC1CYP3A4 | |
| SCHEMBL14682655 | 0.79 | LMNA (0.31) | LMNAPOLB | |
| SCHEMBL12222033 | 0.77 | MMP2 (0.39) | LMNAPKMKDM4ENPC1CYP3A4 | |
| SCHEMBL2297429 | 0.77 | MMP2 (0.44) | LMNAPKMKDM4ENPC1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031887-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031887-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | GABRA3, GABRA4, AVPR1B | LMNA 2301/4885PKM 1828/4885KDM4E 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.